| 1001 | LGALS8/TXNDC5 ratio | GCST90315321 | 15.68 |
| 1002 | Cholesteryl Esters in Large HDL | GCST90497751 | 15.65 |
| 1003 | Cholesterol in Large HDL | GCST90497709 | 15.62 |
| 1004 | Polyunsaturated fatty acid levels | GCST90502606 | 15.62 |
| 1005 | Total lipids in VLDL (UKB data field 23424) | GCST90269521 | 15.57 |
| 1006 | Multi-trait sex score | GCST90270118 | 15.56 |
| 1007 | Triglycerides in small HDL (UKB data field 23578) | GCST90269675 | 15.56 |
| 1008 | SPARC/TACC3 ratio | GCST90315872 | 15.55 |
| 1009 | CERT/MAX ratio | GCST90314028 | 15.55 |
| 1010 | Phospholipids to Total Lipids in Very Large VLDL percentage | GCST90500655 | 15.54 |
| 1011 | TGFA levels | GCST90470842 | 15.50 |
| 1012 | S100P levels | GCST90470520 | 15.50 |
| 1013 | Other noninfective gastroenteritis and colitis | FING00001077 | 15.49 |
| 1014 | FKBP7 levels | GCST90469245 | 15.49 |
| 1015 | Bipolar and major depression status - No Bipolar or Depression | Mental health | UKBB00000094 | 15.49 |
| 1016 | CST7 levels | GCST90468897 | 15.48 |
| 1017 | Cucumber liking | GCST90094749 | 15.47 |
| 1018 | CCL17/F2R ratio | GCST90313686 | 15.47 |
| 1019 | GLB1/PCSK9 ratio | GCST90314933 | 15.43 |
| 1020 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502372 | 15.43 |
| 1021 | Free cholesterol in large LDL | GCST90497981 | 15.40 |
| 1022 | Cholesteryl Esters to Total Lipids in Very Large VLDL percentage | GCST90500565 | 15.40 |
| 1023 | Phenylalanine levels | GCST90499223 | 15.40 |
| 1024 | Cholesterol to total lipids ratio in large LDL | GCST90092857 | 15.38 |
| 1025 | Phospholipids to total lipids ratio in very large HDL | GCST90093013 | 15.37 |
| 1026 | GSTA1/SULT2A1 ratio | GCST90314996 | 15.36 |
| 1027 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502373 | 15.34 |
| 1028 | IDP dMRI TBSS ICVF Sagittal stratum L | GCST90004358 | 15.32 |
| 1029 | Linoleic acid levels | GCST90502311 | 15.32 |
| 1030 | wg rh intensity-contrast entorhinal | GCST90003832 | 15.29 |
| 1031 | Phospholipids in medium HDL (UKB data field 23567) | GCST90269664 | 15.29 |
| 1032 | Chronic iridocyclitis | FING00000287 | 15.24 |
| 1033 | IDP dMRI TBSS FA Cingulum cingulate gyrus R | GCST90003911 | 15.24 |
| 1034 | Cholesteryl ester levels in very large VLDL | GCST90093018 | 15.24 |
| 1035 | HTRA2/SIAE ratio | GCST90315097 | 15.23 |
| 1036 | Monounsaturated fatty acids levels (UKB data field 23447) | GCST90269544 | 15.23 |
| 1037 | Total fatty acid levels | GCST90502727 | 15.22 |
| 1038 | Triglycerides to total lipids ratio in large HDL | GCST90092855 | 15.21 |
| 1039 | DIABLO/VSIR ratio | GCST90314470 | 15.21 |
| 1040 | CCL14 levels | GCST90468566 | 15.19 |
| 1041 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502384 | 15.19 |
| 1042 | Divergent concomitant strabismus | FING00000470 | 15.18 |
| 1043 | ST3GAL1 levels | GCST90470752 | 15.18 |
| 1044 | DIPK2B levels | GCST90468996 | 15.18 |
| 1045 | CST3/CTSZ ratio | GCST90314290 | 15.17 |
| 1046 | Cholesterol levels in chylomicrons and extremely large VLDL | GCST90500905 | 15.15 |
| 1047 | white blood cell count (WBC, mean, inv-norm transformed) | GCST90476454 | 15.14 |
| 1048 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90500994 | 15.13 |
| 1049 | HGF/MMP8 ratio | GCST90315055 | 15.13 |
| 1050 | Cholesteryl esters in large VLDL (UKB data field 23499) | GCST90269596 | 15.13 |
| 1051 | Monounsaturated fatty acid levels | GCST90499090 | 15.12 |
| 1052 | Crohn's disease | GCST004132 | 15.12 |
| 1053 | DKK1 levels | GCST90012060 | 15.12 |
| 1054 | Cholesterol levels in chylomicrons and extremely large VLDL | GCST90093040 | 15.11 |
| 1055 | Cholesteryl Esters to Total Lipids in Large VLDL percentage | GCST90498162 | 15.08 |
| 1056 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502049 | 15.07 |
| 1057 | CD84/SORT1 ratio | GCST90313918 | 15.06 |
| 1058 | Cholesterol to total lipids ratio in medium HDL | GCST90092893 | 15.05 |
| 1059 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502181 | 15.05 |
| 1060 | Phospholipids in small VLDL | GCST90499881 | 15.04 |
| 1061 | LGALS9/SIGLEC1 ratio | GCST90315323 | 15.04 |
| 1062 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90500949 | 15.03 |
| 1063 | Omega-3 fatty acid levels | GCST90502062 | 15.03 |
| 1064 | VSNL1 levels | GCST90471054 | 15.02 |
| 1065 | DUT levels | GCST90469054 | 15.02 |
| 1066 | CD274/EFNA4 ratio | GCST90313768 | 15.00 |
| 1067 | Cholesterol to Total Lipids in Large VLDL percentage | GCST90498130 | 15.00 |
| 1068 | MPO levels | GCST90469937 | 14.98 |
| 1069 | PAPPA levels | GCST90470157 | 14.97 |
| 1070 | CCL8 levels | GCST90468586 | 14.95 |
| 1071 | Cholesterol to Total Lipids in Large VLDL percentage | GCST90498125 | 14.94 |
| 1072 | LGMN levels | GCST90469766 | 14.90 |
| 1073 | rfMRI amplitudes (ICA100 node 15) | GCST90004603 | 14.90 |
| 1074 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90501031 | 14.89 |
| 1075 | triglyceride (minimum, inv-norm transformed) | GCST90476439 | 14.88 |
| 1076 | ANXA3/ANXA4 ratio | GCST90313278 | 14.86 |
| 1077 | APOM levels | GCST90468342 | 14.84 |
| 1078 | GSR levels | GCST90469410 | 14.83 |
| 1079 | DCXR/GSTA1 ratio | GCST90314437 | 14.83 |
| 1080 | MSRA/P4HB ratio | GCST90315495 | 14.83 |
| 1081 | CD69/PLXNA4 ratio | GCST90313880 | 14.81 |
| 1082 | C9 levels | GCST90468505 | 14.81 |
| 1083 | Recent feelings or nervousness or anxiety | Anxiety | UKBB00000741 | 14.80 |
| 1084 | DBH levels | GCST90468948 | 14.80 |
| 1085 | CCN2/ENO2 ratio | GCST90313712 | 14.80 |
| 1086 | Cholesteryl Esters in Medium LDL | GCST90498738 | 14.79 |
| 1087 | DAG1/MGLL ratio | GCST90314377 | 14.78 |
| 1088 | Cholesteryl esters to total lipids in large HDL percentage (UKB data field 23636) | GCST90269733 | 14.78 |
| 1089 | PCDH17 levels | GCST90470169 | 14.77 |
| 1090 | Omega-3 fatty acids to total fatty acids percentage | GCST90502087 | 14.76 |
| 1091 | F-cake/biscuits liking (derived food-liking factor) | GCST90094722 | 14.74 |
| 1092 | IFNGR2 levels | GCST90469514 | 14.74 |
| 1093 | CD244/TREML2 ratio | GCST90313767 | 14.73 |
| 1094 | Triglycerides to total lipids in large HDL percentage (UKB data field 23638) | GCST90269735 | 14.73 |
| 1095 | Cholesteryl Esters to Total Lipids in Small LDL percentage | GCST90499595 | 14.73 |
| 1096 | Concentration of small VLDL particles | GCST90499856 | 14.72 |
| 1097 | Omega-6 fatty acid levels | GCST90502103 | 14.71 |
| 1098 | Linoleic acid levels | GCST90502012 | 14.70 |
| 1099 | Triglycerides in small LDL (UKB data field 23550) | GCST90269647 | 14.70 |
| 1100 | ACHE levels | GCST90468199 | 14.69 |
| 1101 | ENO2/HCLS1 ratio | GCST90314660 | 14.69 |
| 1102 | CLTA levels | GCST90468791 | 14.68 |
| 1103 | Free cholesterol in small VLDL | GCST90499808 | 14.67 |
| 1104 | Free cholesterol to total lipids ratio in large HDL | GCST90092849 | 14.65 |
| 1105 | Cholesterol levels in very large HDL | GCST90500310 | 14.62 |
| 1106 | Triglycerides in VLDL | GCST90500295 | 14.61 |
| 1107 | Free Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500593 | 14.61 |
| 1108 | HNMT levels | GCST90469468 | 14.59 |
| 1109 | FCER2/TREML2 ratio | GCST90314792 | 14.57 |
| 1110 | PLIN3/TYMP ratio | GCST90315678 | 14.57 |
| 1111 | Cholesteryl esters to total lipids ratio in large HDL | GCST90092847 | 14.55 |
| 1112 | COL3A1 levels | GCST90468817 | 14.54 |
| 1113 | IDP dMRI TBSS ICVF Posterior limb of internal capsule R | GCST90004345 | 14.54 |
| 1114 | Phosphatidylcholine levels | GCST90499240 | 14.53 |
| 1115 | HGF/MMP9 ratio | GCST90315056 | 14.52 |
| 1116 | Degree of unsaturation | GCST90502749 | 14.52 |
| 1117 | RGMB/SMOC2 ratio | GCST90315770 | 14.52 |
| 1118 | HYAL1 levels | GCST90469495 | 14.51 |
| 1119 | aparc-a2009s rh area S-oc-middle+Lunatus | GCST90003427 | 14.50 |
| 1120 | CLEC1A/CLEC7A ratio | GCST90314083 | 14.49 |
| 1121 | Ulcerative colitis, NAS | FING00001390 | 14.48 |
| 1122 | Degree of unsaturation | GCST90500162 | 14.48 |
| 1123 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90501075 | 14.48 |
| 1124 | high density lipoprotein cholesterol (HDLC, maximum, inv-norm transformed) | GCST90475348 | 14.46 |
| 1125 | APOBR levels | GCST90468334 | 14.43 |
| 1126 | DSCAM levels | GCST90469041 | 14.43 |
| 1127 | Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500539 | 14.40 |
| 1128 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 80) | GCST90320643 | 14.39 |
| 1129 | Triglycerides to total lipids in small HDL percentage (UKB data field 23648) | GCST90269745 | 14.39 |
| 1130 | FIS1/HSPA1A ratio | GCST90314825 | 14.37 |
| 1131 | CD300C/GOLM2 ratio | GCST90313788 | 14.35 |
| 1132 | Parkinson's disease or first degree relation to individual with Parkinson's disease | GCST009325 | 14.33 |
| 1133 | Total lipids in small VLDL | GCST90499840 | 14.33 |
| 1134 | CD164/SIAE ratio | GCST90313744 | 14.30 |
| 1135 | FUT3_FUT5/LILRA2 ratio | GCST90314889 | 14.28 |
| 1136 | DCTPP1 levels | GCST90468961 | 14.25 |
| 1137 | CASP8/DDX58 ratio | GCST90313651 | 14.25 |
| 1138 | Total Lipids in VLDL | GCST90500236 | 14.25 |
| 1139 | Cardiac pacemaker in situ (PheCode 426.91) | GCST90475960 | 14.24 |
| 1140 | Total lipid levels in VLDL | GCST90092999 | 14.22 |
| 1141 | CLEC4G/SEMA3F ratio | GCST90314123 | 14.21 |
| 1142 | CANT1 levels | GCST90468536 | 14.20 |
| 1143 | Type 2 diabetes | GCST005413 | 14.20 |
| 1144 | Omega-6 fatty acids to total fatty acids percentage | GCST90502129 | 14.15 |
| 1145 | CD164 levels | GCST90468602 | 14.15 |
| 1146 | MYOC levels | GCST90469983 | 14.15 |
| 1147 | ADH1B levels | GCST90468243 | 14.14 |
| 1148 | SEMA7A levels | GCST90470575 | 14.14 |
| 1149 | ITGB1 levels | GCST90469643 | 14.13 |
| 1150 | Triglyceride levels in medium LDL | GCST90092914 | 14.12 |
| 1151 | Phospholipids to Total Lipids in Very Small VLDL percentage | GCST90500866 | 14.09 |
| 1152 | CD84/VASH1 ratio | GCST90313920 | 14.09 |
| 1153 | Free cholesterol in large LDL | GCST90497987 | 14.07 |
| 1154 | ALCAM levels | GCST90468279 | 14.05 |
| 1155 | CST3/RETN ratio | GCST90314297 | 14.03 |
| 1156 | NOTCH2 levels | GCST90470066 | 14.03 |
| 1157 | CCL17/CD69 ratio | GCST90313684 | 14.02 |
| 1158 | Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500542 | 14.01 |
| 1159 | Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500716 | 13.98 |
| 1160 | VSTM1 levels | GCST90471055 | 13.98 |
| 1161 | CD40/IGSF8 ratio | GCST90313815 | 13.97 |
| 1162 | Pain in throat and chest | Symptoms and signs involving the circulatory and respiratory systems | UKBB00000625 | 13.96 |
| 1163 | NPL levels | GCST90470072 | 13.95 |
| 1164 | ADH4/RBP5 ratio | GCST90313194 | 13.94 |
| 1165 | CCL13 levels | GCST90468565 | 13.92 |
| 1166 | Concentration of chylomicrons and extremely large VLDL particles | GCST90093047 | 13.92 |
| 1167 | CXCL17/SFTPA2 ratio | GCST90314341 | 13.91 |
| 1168 | severe traumatic brain injury, does not include concussion | FING00001300 | 13.91 |
| 1169 | DKK1/VASH1 ratio | GCST90314482 | 13.89 |
| 1170 | Docosahexaenoic acid levels | GCST90501978 | 13.89 |
| 1171 | LBR/PSRC1 ratio | GCST90315300 | 13.89 |
| 1172 | TMPRSS5 levels | GCST90470893 | 13.88 |
| 1173 | Other Crohn's disease | FING00000992 | 13.88 |
| 1174 | Cholesteryl Esters to Total Lipids in Small VLDL percentage | GCST90499800 | 13.87 |
| 1175 | Triglycerides in IDL | GCST90497661 | 13.84 |
| 1176 | MEGF9 levels | GCST90469884 | 13.83 |
| 1177 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502043 | 13.81 |
| 1178 | HGF/PLAUR ratio | GCST90315059 | 13.81 |
| 1179 | GLOD4/HSPA1A ratio | GCST90314937 | 13.81 |
| 1180 | Polyunsaturated fatty acid levels | GCST90499266 | 13.80 |
| 1181 | ALDH1A1/CA3 ratio | GCST90313244 | 13.78 |
| 1182 | PTPRB levels | GCST90470379 | 13.77 |
| 1183 | Omega-3 fatty acid levels | GCST90502056 | 13.76 |
| 1184 | ANPEP/DPP4 ratio | GCST90313273 | 13.75 |
| 1185 | FBP1 levels | GCST90469195 | 13.73 |
| 1186 | Cholesteryl ester (16:2) levels | GCST90025238 | 13.70 |
| 1187 | Cholesterol to total lipids in large LDL percentage (UKB data field 23615) | GCST90269712 | 13.70 |
| 1188 | CDH3/TNFRSF21 ratio | GCST90313953 | 13.70 |
| 1189 | CPM levels | GCST90240598 | 13.68 |
| 1190 | F9 levels | GCST90469172 | 13.67 |
| 1191 | IL1RN levels | GCST90469576 | 13.67 |
| 1192 | Exotropia | GCST90572737 | 13.67 |
| 1193 | CCDC80/CCL27 ratio | GCST90313669 | 13.66 |
| 1194 | Cholesterol in IDL | GCST90497501 | 13.65 |
| 1195 | Cholesteryl esters in very large VLDL | GCST90500552 | 13.64 |
| 1196 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501091 | 13.62 |
| 1197 | Concentration of medium LDL particles | GCST90498819 | 13.62 |
| 1198 | CRADD/MAP4K5 ratio | GCST90314240 | 13.61 |
| 1199 | DTI autoptx L3 unc r tract | GCST90385219 | 13.60 |
| 1200 | Triglycerides in HDL | GCST90497464 | 13.60 |
| 1201 | Phospholipid levels in small HDL | GCST90092952 | 13.59 |
| 1202 | Skin brightness | GCST90502777 | 13.59 |
| 1203 | Alzheimer's disease (MTAG) | GCST90449058 | 13.59 |
| 1204 | SIGLEC8 levels | GCST90470636 | 13.57 |
| 1205 | PSRC1 levels | GCST90470365 | 13.57 |
| 1206 | Physical decline (log-difference score) | GCST90565847 | 13.54 |
| 1207 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502411 | 13.53 |
| 1208 | DAB2/FKBP5 ratio | GCST90314363 | 13.52 |
| 1209 | IFI30 levels | GCST90469509 | 13.50 |
| 1210 | Cholesteryl Esters to Total Lipids in Very Small VLDL percentage | GCST90500754 | 13.50 |
| 1211 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 112) | GCST90320931 | 13.50 |
| 1212 | LAT2/SERPINB1 ratio | GCST90315279 | 13.50 |
| 1213 | Triglycerides | Blood biochemistry | UKBB00000861 | 13.48 |
| 1214 | Membranous nephropathy | GCST010006 | 13.48 |
| 1215 | SLAMF8 levels | GCST90470652 | 13.46 |
| 1216 | Phosphatidylcholines levels (UKB data field 23437) | GCST90269534 | 13.46 |
| 1217 | CEP43/PLXNB3 ratio | GCST90314020 | 13.46 |
| 1218 | Alzheimer's disease (MTAG) | GCST90449053 | 13.46 |
| 1219 | Triglyceride levels in very small VLDL | GCST90093038 | 13.44 |
| 1220 | HLA-DRA levels | GCST90469458 | 13.44 |
| 1221 | Total fatty acid levels | GCST90502710 | 13.43 |
| 1222 | HPCAL1/SERPINB9 ratio | GCST90315079 | 13.41 |
| 1223 | FCER2/FCRL1 ratio | GCST90314789 | 13.40 |
| 1224 | MMP8 levels | GCST90469922 | 13.40 |
| 1225 | Phospholipids in chylomicrons and extremely large VLDL (UKB data field 23483) | GCST90269580 | 13.38 |
| 1226 | Cholesterol to Total Lipids in Small VLDL percentage | GCST90499764 | 13.37 |
| 1227 | Linoleic acid to total fatty acids percentage (UKB data field 23456) | GCST90269553 | 13.37 |
| 1228 | CRIP2 levels | GCST90468864 | 13.37 |
| 1229 | PBXIP1 levels | GCST90470164 | 13.37 |
| 1230 | ICAM1/REG1A ratio | GCST90315114 | 13.37 |
| 1231 | ITGA5/SELE ratio | GCST90315205 | 13.36 |
| 1232 | Cholesterol in Small VLDL | GCST90499746 | 13.36 |
| 1233 | Concentration of medium VLDL particles | GCST90499016 | 13.36 |
| 1234 | Phospholipid levels in chylomicrons and extremely large VLDL | GCST90093048 | 13.35 |
| 1235 | LAMP1 levels | GCST90469733 | 13.35 |
| 1236 | KYNU levels | GCST90469722 | 13.35 |
| 1237 | Cereal type: Other (e.g. Cornflakes, Frosties) (UKB data field 1468_5) | GCST90132973 | 13.34 |
| 1238 | HDL cholesterol | GCST000755 | 13.34 |
| 1239 | PROK1 levels | GCST90470336 | 13.32 |
| 1240 | Monounsaturated fatty acids to total fatty acids percentage (UKB data field 23454) | GCST90269551 | 13.32 |
| 1241 | Linoleic acid levels | GCST90502294 | 13.29 |
| 1242 | Acute osteomyelitis (PheCode 710.11) | GCST90476222 | 13.28 |
| 1243 | Ratio of monounsaturated fatty acids to total fatty acids | GCST90092929 | 13.28 |
| 1244 | BAX/MAX ratio | GCST90313466 | 13.27 |
| 1245 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502153 | 13.27 |
| 1246 | Acquired toe deformities (PheCode 735.2) | GCST90476249 | 13.26 |
| 1247 | Phospholipids in medium LDL | GCST90498831 | 13.26 |
| 1248 | DNAJB1/PPME1 ratio | GCST90314510 | 13.23 |
| 1249 | DIABLO/DOK2 ratio | GCST90314464 | 13.21 |
| 1250 | ALDH1A1/PKLR ratio | GCST90313245 | 13.21 |
| 1251 | Phospholipids to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501045 | 13.20 |
| 1252 | Free Cholesterol to Total Lipids in IDL percentage | GCST90497579 | 13.19 |
| 1253 | KIAA2013 levels | GCST90469679 | 13.19 |
| 1254 | GFER/VASH1 ratio | GCST90314922 | 13.17 |
| 1255 | Concentration of chylomicrons and extremely large VLDL particles | GCST90501010 | 13.17 |
| 1256 | Triglyceride levels (MTAG) | GCST90179149 | 13.16 |
| 1257 | CD63 levels | GCST90468642 | 13.16 |
| 1258 | Triglycerides | GCST002216 | 13.15 |
| 1259 | Triglycerides in LDL | GCST90498472 | 13.15 |
| 1260 | Left-hemisphere default mode network to putamen white-matter structural connectivity | GCST90302769 | 13.14 |
| 1261 | GSN levels | GCST90469409 | 13.14 |
| 1262 | TDRKH/TST ratio | GCST90315913 | 13.13 |
| 1263 | high density lipoprotein cholesterol (HDLC, mean, inv-norm transformed) | GCST90475352 | 13.13 |
| 1264 | CD74/LILRB4 ratio | GCST90313894 | 13.11 |
| 1265 | Cholesteryl Esters in Large LDL | GCST90497955 | 13.11 |
| 1266 | Docosahexaenoic acid to total fatty acids percentage | GCST90502269 | 13.10 |
| 1267 | Phosphatidylcholine-O_44:5_[M+OAc]1-/Phosphatidylcholine-P_44:4_[M+OAc]1- levels | GCST90060557 | 13.08 |
| 1268 | IL15/KLRD1 ratio | GCST90315149 | 13.06 |
| 1269 | Total Lipids in VLDL | GCST90500234 | 13.05 |
| 1270 | ARSA levels | GCST90468368 | 13.04 |
| 1271 | Monounsaturated fatty acid levels | GCST90502346 | 13.03 |
| 1272 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502385 | 13.03 |
| 1273 | QPCT/RNASET2 ratio | GCST90315758 | 13.03 |
| 1274 | Total lipids in very small VLDL | GCST90500813 | 13.03 |
| 1275 | Omega-6 fatty acid levels | GCST90092933 | 13.02 |
| 1276 | SERPINB6/TXNDC5 ratio | GCST90315832 | 13.02 |
| 1277 | Cholesterol to Total Lipids in Small LDL percentage | GCST90499569 | 13.02 |
| 1278 | LRRN1 levels | GCST90469806 | 13.01 |
| 1279 | Total triglycerides levels | GCST90500140 | 13.00 |
| 1280 | Triglycerides to Total Lipids in Very Small VLDL percentage | GCST90500900 | 13.00 |
| 1281 | Total cholines levels | GCST90497185 | 12.99 |
| 1282 | Otosclerosis | FING00001131 | 12.97 |
| 1283 | IDP SWI T2star left caudate | GCST90003865 | 12.97 |
| 1284 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90501002 | 12.97 |
| 1285 | Triglycerides in HDL | GCST90497467 | 12.96 |
| 1286 | PPCDC/RWDD1 ratio | GCST90315704 | 12.96 |
| 1287 | Omega-3 fatty acid levels | GCST90502437 | 12.95 |
| 1288 | Concentration of small LDL particles | GCST90499660 | 12.95 |
| 1289 | AGRP levels | GCST90468256 | 12.94 |
| 1290 | C4BPB/ENTPD5 ratio | GCST90313556 | 12.94 |
| 1291 | Triglycerides to total lipids ratio in medium HDL | GCST90092903 | 12.93 |
| 1292 | PCSK7 levels | GCST90470176 | 12.93 |
| 1293 | Cholesteryl Esters in LDL | GCST90498374 | 12.93 |
| 1294 | triglyceride (mean, inv-norm transformed) | GCST90476435 | 12.92 |
| 1295 | triglyceride (minimum, inv-norm transformed) | GCST90476437 | 12.92 |
| 1296 | LGMN/TIMP1 ratio | GCST90315325 | 12.91 |
| 1297 | TGFB1 levels | GCST90274818 | 12.90 |
| 1298 | Total lipids in medium VLDL (UKB data field 23503) | GCST90269600 | 12.90 |
| 1299 | CA5A/GRPEL1 ratio | GCST90313590 | 12.89 |
| 1300 | CXCL8 levels | GCST90468934 | 12.89 |
| 1301 | Cholesterol to total lipids in medium HDL percentage (UKB data field 23640) | GCST90269737 | 12.87 |
| 1302 | HNMT/SETMAR ratio | GCST90315069 | 12.85 |
| 1303 | CCL17/THPO ratio | GCST90313689 | 12.85 |
| 1304 | IDP dMRI TBSS L1 Genu of corpus callosum | GCST90004077 | 12.82 |
| 1305 | Job involves shift work | Employment | UKBB00000385 | 12.82 |
| 1306 | Phospholipids in large HDL | GCST90497847 | 12.82 |
| 1307 | HSPB6 levels | GCST90469490 | 12.82 |
| 1308 | AOC3 levels | GCST90468322 | 12.81 |
| 1309 | Monocyte count | GCST90002341 | 12.81 |
| 1310 | Phospholipids to Total Lipids in Medium VLDL percentage | GCST90499043 | 12.80 |
| 1311 | Total fatty acid levels | GCST90092987 | 12.79 |
| 1312 | Ulcerative colitis (strict) with PSC | FING00001389 | 12.78 |
| 1313 | Free Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498988 | 12.77 |
| 1314 | Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500956 | 12.77 |
| 1315 | APOA2 levels | GCST90468332 | 12.76 |
| 1316 | Cereal type - Other (e.g. Cornflakes, Frosties) | Diet | UKBB00000125 | 12.76 |
| 1317 | Dementia, including avohilmo | FING00000395 | 12.76 |
| 1318 | FGFBP2 levels | GCST90469231 | 12.73 |
| 1319 | Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500992 | 12.73 |
| 1320 | VWA1 levels | GCST90471061 | 12.72 |
| 1321 | F11R/TMSB10 ratio | GCST90314729 | 12.71 |
| 1322 | Phospholipids to Total Lipids in IDL percentage | GCST90497642 | 12.70 |
| 1323 | Triglycerides in LDL | GCST90498469 | 12.68 |
| 1324 | Triglycerides in large LDL | GCST90498083 | 12.67 |
| 1325 | IDP T1 FIRST right pallidum volume | GCST90002443 | 12.65 |
| 1326 | MSR1/TNFRSF21 ratio | GCST90315494 | 12.64 |
| 1327 | Free cholesterol in small LDL | GCST90499620 | 12.63 |
| 1328 | CCL14/CST3 ratio | GCST90313679 | 12.60 |
| 1329 | Raw carrot liking | GCST90094818 | 12.59 |
| 1330 | TNFRSF13B/TNFRSF13C ratio | GCST90315931 | 12.59 |
| 1331 | Free Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500791 | 12.59 |
| 1332 | F10 levels | GCST90469163 | 12.56 |
| 1333 | IL6ST/LIFR ratio | GCST90315166 | 12.56 |
| 1334 | CFHR4 levels | GCST90468727 | 12.54 |
| 1335 | Linoleic acid levels | GCST90502004 | 12.54 |
| 1336 | CSF1/LTBR ratio | GCST90314287 | 12.54 |
| 1337 | Phospholipids to Total Lipids in Small HDL percentage | GCST90499505 | 12.53 |
| 1338 | Abdominal subcutaneous adipose tissue volume | GCST90016672 | 12.53 |
| 1339 | OMD levels | GCST90470123 | 12.52 |
| 1340 | CEACAM8/VNN2 ratio | GCST90314005 | 12.51 |
| 1341 | OMD/SOST ratio | GCST90315585 | 12.50 |
| 1342 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501092 | 12.47 |
| 1343 | FGR/LBR ratio | GCST90314814 | 12.46 |
| 1344 | EREG/MPI ratio | GCST90314705 | 12.45 |
| 1345 | KLRD1 levels | GCST90469711 | 12.45 |
| 1346 | NRCAM/NTRK2 ratio | GCST90315552 | 12.44 |
| 1347 | TPK1 levels | GCST90470943 | 12.43 |
| 1348 | Degree of unsaturation | GCST90502746 | 12.43 |
| 1349 | ADH4 levels | GCST90468244 | 12.43 |
| 1350 | Concentration of VLDL particles | GCST90500246 | 12.42 |
| 1351 | DFFA/FOXO1 ratio | GCST90314456 | 12.42 |
| 1352 | Cholesteryl Esters in Small VLDL | GCST90499782 | 12.41 |
| 1353 | Triglycerides in medium LDL (UKB data field 23543) | GCST90269640 | 12.41 |
| 1354 | KITLG levels | GCST90012023 | 12.41 |
| 1355 | Free cholesterol in chylomicrons and extremely large VLDL (UKB data field 23486) | GCST90269583 | 12.41 |
| 1356 | APRT/CD63 ratio | GCST90313334 | 12.41 |
| 1357 | CLEC1B/MGLL ratio | GCST90314097 | 12.41 |
| 1358 | Free cholesterol in medium LDL | GCST90498767 | 12.40 |
| 1359 | CD302/CD99 ratio | GCST90313805 | 12.39 |
| 1360 | high density lipoprotein cholesterol (HDLC, minimm, inv-norm transformed) | GCST90475356 | 12.39 |
| 1361 | CTHRC1 levels | GCST90468902 | 12.39 |
| 1362 | Free Cholesterol to Total Lipids in Small VLDL percentage | GCST90499832 | 12.37 |
| 1363 | MEPE/SOST ratio | GCST90315420 | 12.37 |
| 1364 | ASAH1 levels | GCST90468373 | 12.37 |
| 1365 | Concentration of small VLDL particles (UKB data field 23509) | GCST90269606 | 12.34 |
| 1366 | COL18A1/RARRES2 ratio | GCST90314169 | 12.34 |
| 1367 | HCLS1/TMSB10 ratio | GCST90315043 | 12.32 |
| 1368 | CLEC1B/SORT1 ratio | GCST90314104 | 12.32 |
| 1369 | FHIT/PARK7 ratio | GCST90314821 | 12.32 |
| 1370 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500929 | 12.31 |
| 1371 | Triglycerides in small VLDL | GCST90499917 | 12.31 |
| 1372 | Total lipids in small LDL | GCST90499652 | 12.31 |
| 1373 | DCXR/KYNU ratio | GCST90314438 | 12.30 |
| 1374 | ACVRL1/TNFRSF10B ratio | GCST90313158 | 12.30 |
| 1375 | CLEC1B/SNAP29 ratio | GCST90314103 | 12.28 |
| 1376 | ITGB5/VSIR ratio | GCST90315235 | 12.28 |
| 1377 | Phosphoglycerides levels (UKB data field 23434) | GCST90269531 | 12.24 |
| 1378 | DBNL/DNAJA2 ratio | GCST90314415 | 12.23 |
| 1379 | RRM2 levels | GCST90470501 | 12.22 |
| 1380 | Ever worried more than most people would in similar situation | Anxiety | UKBB00000227 | 12.20 |
| 1381 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502074 | 12.19 |
| 1382 | Cholesterol in Large VLDL | GCST90498119 | 12.19 |
| 1383 | NID1 levels | GCST90470047 | 12.17 |
| 1384 | Cholesterol to Total Lipids in IDL percentage | GCST90497518 | 12.15 |
| 1385 | IQGAP2/STX4 ratio | GCST90315190 | 12.15 |
| 1386 | LBR/MAD1L1 ratio | GCST90315295 | 12.13 |
| 1387 | NAGK levels | GCST90469995 | 12.13 |
| 1388 | Concentration of very small VLDL particles | GCST90500826 | 12.13 |
| 1389 | F-capsicum liking (derived food-liking factor) | GCST90094726 | 12.12 |
| 1390 | Cholesteryl Esters in VLDL | GCST90500211 | 12.12 |
| 1391 | F2R/SPINT2 ratio | GCST90314737 | 12.12 |
| 1392 | aseg rh intensity Putamen | GCST90003784 | 12.12 |
| 1393 | Cholesterol to Total Lipids in Medium VLDL percentage | GCST90498919 | 12.11 |
| 1394 | TNFRSF11B levels | GCST90470903 | 12.11 |
| 1395 | CREG1 levels | GCST90468857 | 12.11 |
| 1396 | MITD1/RHOC ratio | GCST90315453 | 12.11 |
| 1397 | End-diastolic bi-ventricular shape (principal component 8) | GCST90448487 | 12.10 |
| 1398 | Phosphoglycerides levels | GCST90499259 | 12.09 |
| 1399 | ORM1 levels | GCST90470129 | 12.08 |
| 1400 | Cholesteryl ester levels in large VLDL | GCST90092870 | 12.08 |
| 1401 | ATP5IF1/F2R ratio | GCST90313384 | 12.06 |
| 1402 | IDP T1 FAST ROIs L ventral striatum | GCST90002559 | 12.06 |
| 1403 | DNAJA2/PLXNA4 ratio | GCST90314504 | 12.05 |
| 1404 | EREG/ITGB1BP2 ratio | GCST90314703 | 12.05 |
| 1405 | MCEE levels | GCST90469871 | 12.04 |
| 1406 | Diacylglycerol_36:3_[M+H-H2O]1+ levels | GCST90060189 | 12.04 |
| 1407 | Cheese intake | Diet | UKBB00000127 | 12.03 |
| 1408 | BLVRB/CA3 ratio | GCST90313523 | 12.01 |
| 1409 | BRK1 levels | GCST90468469 | 11.99 |
| 1410 | VLDL cholesterol levels | GCST90500196 | 11.99 |
| 1411 | Medication for pain relief, constipation, heartburn - Ibuprofen (e.g. Nurofen) | Medication | UKBB00000455 | 11.98 |
| 1412 | BGLAP levels | GCST90468440 | 11.98 |
| 1413 | ICAM3/SLAMF7 ratio | GCST90315123 | 11.98 |
| 1414 | FAP/THBS4 ratio | GCST90314785 | 11.98 |
| 1415 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90132630 | 11.96 |
| 1416 | Myocardial fractal dimension (slice 5) | GCST90000291 | 11.95 |
| 1417 | HCLS1/LAT ratio | GCST90315041 | 11.95 |
| 1418 | PLAU levels | GCST90470252 | 11.95 |
| 1419 | GOLM2/ITGA5 ratio | GCST90314951 | 11.94 |
| 1420 | IDP dMRI TBSS ICVF Cerebral peduncle L | GCST90004342 | 11.94 |
| 1421 | triglyceride (maximum, inv-norm transformed) | GCST90476431 | 11.94 |
| 1422 | Cholesteryl esters to total lipids ratio in very small VLDL | GCST90093031 | 11.93 |
| 1423 | Freckles | GCST006091 | 11.93 |
| 1424 | CLEC1B/DIABLO ratio | GCST90314087 | 11.93 |
| 1425 | MDGA1 levels | GCST90469875 | 11.93 |
| 1426 | Ulcerative proctitis | FING00001393 | 11.92 |
| 1427 | ART3/RGMB ratio | GCST90313363 | 11.91 |
| 1428 | HSPB1/QDPR ratio | GCST90315089 | 11.90 |
| 1429 | CKMB levels | GCST90475221 | 11.90 |
| 1430 | ESAM/THPO ratio | GCST90314719 | 11.89 |
| 1431 | ALCAM/IL1RL2 ratio | GCST90313238 | 11.88 |
| 1432 | Omega-3 fatty acids to total fatty acids percentage | GCST90502463 | 11.88 |
| 1433 | Accelerometer-based physical activity measurement (average acceleration) | GCST006099 | 11.88 |
| 1434 | CXCL16 levels | GCST90012059 | 11.88 |
| 1435 | Birth year infant mortality rates | GCST90095047 | 11.87 |
| 1436 | Free cholesterol in very small VLDL | GCST90500774 | 11.87 |
| 1437 | Noninfective enteritis and colitis | FING00000881 | 11.86 |
| 1438 | Remnant cholesterol (non-HDL, non-LDL -cholesterol) | GCST90499340 | 11.86 |
| 1439 | CLEC1B/MPIG6B ratio | GCST90314098 | 11.86 |
| 1440 | Linoleic acid levels | GCST90498306 | 11.84 |
| 1441 | FGL1 levels | GCST90469235 | 11.84 |
| 1442 | Total phospholipid levels in lipoprotein particles | GCST90092991 | 11.83 |
| 1443 | Saturated fatty acids levels | GCST90502194 | 11.83 |
| 1444 | Cholesteryl Esters to Total Lipids in IDL percentage | GCST90497549 | 11.82 |
| 1445 | Omega-6 fatty acids levels (UKB data field 23445) | GCST90269542 | 11.80 |
| 1446 | RNASE6 levels | GCST90470479 | 11.79 |
| 1447 | Dementia | FING00000391 | 11.79 |
| 1448 | IDP dMRI TBSS ICVF Fornix cres+Stria terminalis L | GCST90004366 | 11.79 |
| 1449 | KLK6/PTPRN2 ratio | GCST90315256 | 11.79 |
| 1450 | CLEC4G/KEL ratio | GCST90314119 | 11.79 |
| 1451 | Degree of unsaturation | GCST90502231 | 11.78 |
| 1452 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502555 | 11.78 |
| 1453 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499111 | 11.78 |
| 1454 | Free cholesterol levels in chylomicrons and extremely large VLDL | GCST90093044 | 11.77 |
| 1455 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499109 | 11.77 |
| 1456 | CRADD/DARS1 ratio | GCST90314234 | 11.76 |
| 1457 | IZUMO4 levels | GCST90423792 | 11.75 |
| 1458 | Octadecenedioate (C18:1-DC) levels | GCST90200165 | 11.75 |
| 1459 | LILRB4 levels | GCST90469778 | 11.75 |
| 1460 | CDKN1A/TXLNA ratio | GCST90313979 | 11.75 |
| 1461 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502566 | 11.74 |
| 1462 | Phosphatidylcholine-O_32:1_[M+H]1+/Phosphatidylcholine-P_32:0_[M+H]1+/Phosphatidylethanolamine-O_35:1_[M+H]1+ levels | GCST90060254 | 11.71 |
| 1463 | ADGRF5 levels | GCST90468239 | 11.70 |
| 1464 | IL1R1/IL1RN ratio | GCST90315158 | 11.69 |
| 1465 | Triglycerides in small LDL | GCST90499712 | 11.69 |
| 1466 | Docosahexaenoic acid to total fatty acids percentage | GCST90497268 | 11.68 |
| 1467 | HPGDS/ITGAV ratio | GCST90315080 | 11.67 |
| 1468 | Salty food liking | GCST90094828 | 11.66 |
| 1469 | Omega-6 fatty acid levels | GCST90502502 | 11.66 |
| 1470 | LCN2/S100A12 ratio | GCST90315309 | 11.66 |
| 1471 | Cholesteryl ester levels in chylomicrons and extremely large VLDL | GCST90500943 | 11.65 |
| 1472 | DCBLD2/PLA2G15 ratio | GCST90314428 | 11.65 |
| 1473 | IL6 expression at 6 weeks in whole blood upon Bbmix moi30 stimulation in Lyme borreliosis | GCST90275789 | 11.64 |
| 1474 | NAGA levels | GCST90469994 | 11.64 |
| 1475 | Plasma 1-arachidonoyl-GPE (20:4n6)* levels in chronic kidney disease | GCST90264207 | 11.64 |
| 1476 | CASP3/CRKL ratio | GCST90313631 | 11.63 |
| 1477 | ENO2/PLXNA4 ratio | GCST90314665 | 11.63 |
| 1478 | LDL cholesterol levels | GCST90498346 | 11.63 |
| 1479 | Left-hemisphere visual network to caudate white-matter structural connectivity | GCST90302663 | 11.62 |
| 1480 | F5 levels | GCST90446466 | 11.62 |
| 1481 | MANSC4 levels | GCST90469848 | 11.61 |
| 1482 | Concentration of chylomicrons and extremely large VLDL particles (UKB data field 23481) | GCST90269578 | 11.58 |
| 1483 | Concentration of small VLDL particles | GCST90092975 | 11.58 |
| 1484 | PLA2G15/SMPDL3A ratio | GCST90315663 | 11.58 |
| 1485 | Cholesteryl Esters in IDL | GCST90497525 | 11.57 |
| 1486 | Principal component-derived dietary pattern 17 | GCST90133022 | 11.56 |
| 1487 | Total Lipids in LDL | GCST90498396 | 11.56 |
| 1488 | CDC37/SNAP29 ratio | GCST90313935 | 11.56 |
| 1489 | ADAMTSL2 levels | GCST90468228 | 11.55 |
| 1490 | Cholesterol in IDL | GCST90497495 | 11.55 |
| 1491 | IDP dMRI TBSS ICVF Cingulum hippocampus L | GCST90004364 | 11.55 |
| 1492 | CD58/IFNGR1 ratio | GCST90313849 | 11.54 |
| 1493 | DPP6/NELL2 ratio | GCST90314541 | 11.53 |
| 1494 | MYLPF levels | GCST90469980 | 11.53 |
| 1495 | Saturated fatty acids levels (UKB data field 23448) | GCST90269545 | 11.53 |
| 1496 | Omega-3 fatty acids to total fatty acids percentage | GCST90499155 | 11.52 |
| 1497 | COMP/TGFBI ratio | GCST90314192 | 11.52 |
| 1498 | Social trust (aggregated) | GCST90319315 | 11.52 |
| 1499 | BAG6/WASF1 ratio | GCST90313452 | 11.47 |
| 1500 | Diacylglycerol_36:2_[M+H-H2O]1+ levels | GCST90060191 | 11.46 |
| 1501 | Total fatty acids levels (UKB data field 23442) | GCST90269539 | 11.46 |
| 1502 | Left ventricular end diastolic mass | GCST90268123 | 11.46 |
| 1503 | APP/FKBP1B ratio | GCST90313323 | 11.45 |
| 1504 | ITGA6/THPO ratio | GCST90315208 | 11.45 |
| 1505 | CPM levels | GCST90468843 | 11.45 |
| 1506 | Phospholipids in VLDL | GCST90500266 | 11.44 |
| 1507 | FCGR3B levels | GCST90469202 | 11.44 |
| 1508 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T104 | ECGU000104 | 11.44 |
| 1509 | Phospholipids in VLDL (UKB data field 23412) | GCST90269509 | 11.44 |
| 1510 | Polyunsaturated fatty acid levels | GCST90502134 | 11.43 |
| 1511 | EREG/HBEGF ratio | GCST90314702 | 11.42 |
| 1512 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90093046 | 11.39 |
| 1513 | Total lipids in IDL | GCST90497594 | 11.39 |
| 1514 | PDGFB levels | GCST90012016 | 11.37 |
| 1515 | Basophil percentage of granulocytes | GCST004634 | 11.37 |
| 1516 | ANGPT1/MPIG6B ratio | GCST90313265 | 11.37 |
| 1517 | Triglycerides to total lipids ratio in very small VLDL | GCST90093039 | 11.35 |
| 1518 | Free cholesterol in IDL | GCST90497564 | 11.34 |
| 1519 | FGF21/LEP ratio | GCST90314810 | 11.34 |
| 1520 | Concentration of small VLDL particles | GCST90499868 | 11.32 |
| 1521 | CD99L2/RARRES2 ratio | GCST90313927 | 11.32 |
| 1522 | MAD1L1 levels | GCST90469836 | 11.31 |
| 1523 | OSM/TGFA ratio | GCST90315590 | 11.31 |
| 1524 | Total cholines levels (UKB data field 23436) | GCST90269533 | 11.31 |
| 1525 | CASP3/SERPINE1 ratio | GCST90313643 | 11.30 |
| 1526 | Right-hemisphere visual network to pallidum white-matter structural connectivity | GCST90302784 | 11.30 |
| 1527 | Free Cholesterol in VLDL | GCST90500221 | 11.30 |
| 1528 | DAG1/PLA2G4A ratio | GCST90314380 | 11.30 |
| 1529 | CD40LG/EDAR ratio | GCST90313818 | 11.30 |
| 1530 | CCN2/SERPINB1 ratio | GCST90313715 | 11.29 |
| 1531 | SPOCK1 levels | GCST90470730 | 11.29 |
| 1532 | CD4/LILRB4 ratio | GCST90313843 | 11.28 |
| 1533 | OLR1/PLAUR ratio | GCST90315584 | 11.28 |
| 1534 | CD27/FCRL5 ratio | GCST90313772 | 11.27 |
| 1535 | Total lipid levels in medium VLDL | GCST90092922 | 11.27 |
| 1536 | PRL levels | GCST90470332 | 11.27 |
| 1537 | Heart rate variability (standard deviation of normal-to-normal intervals) | GCST90281265 | 11.26 |
| 1538 | CALCOCO1/TBC1D5 ratio | GCST90313610 | 11.26 |
| 1539 | Omega-3 fatty acid levels | GCST90502061 | 11.25 |
| 1540 | CD84/SDC4 ratio | GCST90313916 | 11.25 |
| 1541 | Cholesteryl Esters to Total Lipids in Large LDL percentage | GCST90497967 | 11.24 |
| 1542 | Phospholipids in LDL | GCST90498432 | 11.23 |
| 1543 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T103 | ECGU000103 | 11.22 |
| 1544 | CNTN2 levels | GCST90468804 | 11.21 |
| 1545 | BSG/TNFRSF4 ratio | GCST90313536 | 11.19 |
| 1546 | Gout, strict definition | FING00000588 | 11.19 |
| 1547 | Omega-3 fatty acids to total fatty acids percentage | GCST90502460 | 11.19 |
| 1548 | ALKBH3 levels | GCST90619095 | 11.19 |
| 1549 | Volume of right cortico-amygdaloid transition area | GCST90475018 | 11.18 |
| 1550 | ENO2/FXYD5 ratio | GCST90314659 | 11.17 |
| 1551 | CRKL/MANF ratio | GCST90314269 | 11.16 |
| 1552 | Degree of unsaturation | GCST90502230 | 11.15 |
| 1553 | Benign neoplasm: Adrenal gland | FING00000164 | 11.13 |
| 1554 | NT5C3A/PRDX5 ratio | GCST90315567 | 11.12 |
| 1555 | CHMP1A/RHOC ratio | GCST90314053 | 11.11 |
| 1556 | Monounsaturated fatty acid levels | GCST90502030 | 11.10 |
| 1557 | EBAG9/TGFB1 ratio | GCST90314570 | 11.10 |
| 1558 | IDP dMRI TBSS ICVF Retrolenticular part of internal capsule L | GCST90004348 | 11.09 |
| 1559 | IDP dMRI ProbtrackX ISOVF ifo r | GCST90004538 | 11.09 |
| 1560 | CC2D1A/CRADD ratio | GCST90313663 | 11.08 |
| 1561 | Triglycerides | GCST90018755 | 11.08 |
| 1562 | PDGFA/USP8 ratio | GCST90315621 | 11.06 |
| 1563 | Docosahexaenoic acid to total fatty acids percentage | GCST90501991 | 11.06 |
| 1564 | ADAM9 levels | GCST90468221 | 11.06 |
| 1565 | CD300C levels | GCST90468620 | 11.05 |
| 1566 | ERBB2/FURIN ratio | GCST90314686 | 11.05 |
| 1567 | DEFA1_DEFA1B/PTGDS ratio | GCST90314455 | 11.04 |
| 1568 | CX3CL1/LAYN ratio | GCST90314325 | 11.04 |
| 1569 | LTA4H levels | GCST90469812 | 11.04 |
| 1570 | SDC4/SERPINE1 ratio | GCST90315819 | 11.03 |
| 1571 | PLIN1/SNCG ratio | GCST90315677 | 11.02 |
| 1572 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502567 | 11.01 |
| 1573 | CA13/QDPR ratio | GCST90313564 | 11.01 |
| 1574 | FGFR4 levels | GCST90469234 | 11.01 |
| 1575 | CALCOCO1/METAP2 ratio | GCST90313606 | 11.01 |
| 1576 | Cholesteryl esters to total lipids ratio in small LDL | GCST90092959 | 11.00 |
| 1577 | T1 FreeSurfer BA lh BA3a exvivo thickness | GCST90385521 | 11.00 |
| 1578 | Crohn's disease of small intestine | FING00000369 | 10.99 |
| 1579 | Neutrophil count | GCST90018748 | 10.99 |
| 1580 | Hayfever | GCST90468131 | 10.98 |
| 1581 | Saturated fatty acid levels | GCST90092980 | 10.97 |
| 1582 | ACVRL1/TNFRSF9 ratio | GCST90313160 | 10.96 |
| 1583 | Polyunsaturated fatty acid levels | GCST90502142 | 10.96 |
| 1584 | LRTM2 levels | GCST90469808 | 10.95 |
| 1585 | PDGFA/SNAP23 ratio | GCST90315619 | 10.95 |
| 1586 | BPIFB1/GLRX ratio | GCST90313530 | 10.94 |
| 1587 | STC2 levels | GCST90470762 | 10.89 |
| 1588 | ENO2/SULT1A1 ratio | GCST90314669 | 10.88 |
| 1589 | Triglyceride levels in chylomicrons and extremely large VLDL | GCST90093050 | 10.88 |
| 1590 | CD19 on IgD- CD27- B cell | GCST90001732 | 10.87 |
| 1591 | Neuroendocrine tumor and carcinoma of stomach, excluding all cancers (controls excluding all cancers) | FING00000866 | 10.87 |
| 1592 | MCTS1 levels | GCST90469874 | 10.87 |
| 1593 | APOB levels | GCST90497137 | 10.86 |
| 1594 | Omega-3 fatty acid levels | GCST90502424 | 10.85 |
| 1595 | Linoleic acid to total fatty acids percentage | GCST90502025 | 10.85 |
| 1596 | Dimethylglycine levels | GCST90200424 | 10.85 |
| 1597 | DPP6/SEZ6L ratio | GCST90314544 | 10.84 |
| 1598 | Cholesteryl esters to total lipids ratio in medium HDL | GCST90092895 | 10.81 |
| 1599 | IDP dMRI TBSS ICVF Retrolenticular part of internal capsule R | GCST90004347 | 10.80 |
| 1600 | Rotator cuff syndrome | FING00001270 | 10.80 |
| 1601 | ASRGL1 levels | GCST90468379 | 10.79 |
| 1602 | NFKBIE levels | GCST90470039 | 10.79 |
| 1603 | Conditional arithmetic | Fluid intelligence / reasoning | UKBB00000145 | 10.78 |
| 1604 | Omega-6 fatty acids levels | GCST90499170 | 10.78 |
| 1605 | Cholesterol to total lipids ratio in very small VLDL | GCST90093029 | 10.78 |
| 1606 | IL18R1 levels | GCST90469565 | 10.78 |
| 1607 | IDP dMRI TBSS L1 Corticospinal tract R | GCST90004081 | 10.78 |
| 1608 | X-13671 levels | GCST90243829 | 10.76 |
| 1609 | Free cholesterol to total lipids in large LDL percentage (UKB data field 23617) | GCST90269714 | 10.76 |
| 1610 | CLEC1B/PLXNA4 ratio | GCST90314100 | 10.75 |
| 1611 | Phospholipids to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093049 | 10.75 |
| 1612 | BCAN/NCAN ratio | GCST90313481 | 10.75 |
| 1613 | Phospholipids to Total Lipids in Small VLDL percentage | GCST90499902 | 10.75 |
| 1614 | Alanine transaminase (ALT, maximum, inv-norm transformed) | GCST90475109 | 10.74 |
| 1615 | HDL x low social support interaction (2df test) | GCST90570669 | 10.73 |
| 1616 | CHAD levels | GCST90468737 | 10.72 |
| 1617 | Total lipids in chylomicrons and extremely large VLDL (UKB data field 23482) | GCST90269579 | 10.72 |
| 1618 | Monocyte count | GCST90018747 | 10.71 |
| 1619 | FNDC1 levels | GCST90469256 | 10.71 |
| 1620 | CNTN1 levels | GCST90468803 | 10.70 |
| 1621 | Free cholesterol to total lipids ratio in IDL | GCST90092836 | 10.70 |
| 1622 | OSCAR/TNFRSF14 ratio | GCST90315588 | 10.69 |
| 1623 | LGALS1/LGALS8 ratio | GCST90315314 | 10.69 |
| 1624 | Heart rate variability (corrected standard deviation of normal-to-normal intervals) | GCST90281266 | 10.69 |
| 1625 | ANGPT1/CPXM1 ratio | GCST90313262 | 10.69 |
| 1626 | FABP4/SNCG ratio | GCST90314759 | 10.68 |
| 1627 | CST3/RARRES2 ratio | GCST90314295 | 10.67 |
| 1628 | DPT levels | GCST90469036 | 10.67 |
| 1629 | ARSA/CD164 ratio | GCST90313351 | 10.66 |
| 1630 | Triglyceride levels in very large HDL | GCST90132636 | 10.65 |
| 1631 | Cholesteryl esters to total lipids ratio in very large HDL | GCST90093007 | 10.65 |
| 1632 | CLEC1B/DAB2 ratio | GCST90314086 | 10.64 |
| 1633 | Cholesteryl Esters in Small HDL | GCST90499386 | 10.64 |
| 1634 | Cholesterol to Total Lipids in Large LDL percentage | GCST90497938 | 10.64 |
| 1635 | RARRES2 levels | GCST90470428 | 10.64 |
| 1636 | CD80 levels | GCST90468650 | 10.64 |
| 1637 | SPP1 levels | GCST90470733 | 10.64 |
| 1638 | KITLG levels | GCST90469691 | 10.64 |
| 1639 | Fractures | GCST006980 | 10.63 |
| 1640 | NTRK3 levels | GCST90470098 | 10.63 |
| 1641 | DKK1/VTA1 ratio | GCST90314485 | 10.63 |
| 1642 | Modified Stumvoll Insulin Sensitivity Index | GCST90267574 | 10.63 |
| 1643 | Total phospholipids in lipoprotein particles (UKB data field 23411) | GCST90269508 | 10.62 |
| 1644 | CCL11/CCL13 ratio | GCST90313671 | 10.61 |
| 1645 | Cholesterol levels (UKB data field 30690) | GCST90468066 | 10.61 |
| 1646 | Osteomyelitis (PheCode 710.1) | GCST90476221 | 10.61 |
| 1647 | Hard cheese liking | GCST90094778 | 10.60 |
| 1648 | FCGR2A levels | GCST90469200 | 10.59 |
| 1649 | LMNB2 levels | GCST90469782 | 10.59 |
| 1650 | Gestational thrombocytopenia | GCST90302234 | 10.59 |
| 1651 | Chronic nephritic syndrome | FING00000295 | 10.58 |
| 1652 | Free testosterone levels | GCST90239825 | 10.56 |
| 1653 | Triacylglycerol (54:1) [NL-18:1] levels | GCST90024563 | 10.56 |
| 1654 | Polyunsaturated fatty acid levels | GCST90092939 | 10.55 |
| 1655 | DIABLO/PDGFB ratio | GCST90314468 | 10.55 |
| 1656 | HBEGF/LAT2 ratio | GCST90315032 | 10.55 |
| 1657 | S100A11/SERPINB8 ratio | GCST90315799 | 10.53 |
| 1658 | Cholesteryl esters to total lipids ratio in medium VLDL | GCST90092919 | 10.53 |
| 1659 | DBNL/HSPA1A ratio | GCST90314418 | 10.53 |
| 1660 | PLXNA4/VASH1 ratio | GCST90315691 | 10.53 |
| 1661 | ICOSLG levels | GCST90469503 | 10.53 |
| 1662 | PLA2G10 levels | GCST90470244 | 10.51 |
| 1663 | CDC37/PPP1R12A ratio | GCST90313934 | 10.51 |
| 1664 | EREG/TIMP3 ratio | GCST90314708 | 10.50 |
| 1665 | BACH1/NFATC1 ratio | GCST90313444 | 10.49 |
| 1666 | Single spontaneous delivery | FING00001307 | 10.49 |
| 1667 | white blood cell count (WBC, maximum, inv-norm transformed) | GCST90476451 | 10.49 |
| 1668 | CD27/TNFRSF9 ratio | GCST90313778 | 10.49 |
| 1669 | GZMA/TNFRSF8 ratio | GCST90315014 | 10.49 |
| 1670 | BCAN/KLK6 ratio | GCST90313479 | 10.48 |
| 1671 | SERPINE1/VASH1 ratio | GCST90315836 | 10.47 |
| 1672 | CEP43/TIA1 ratio | GCST90314021 | 10.46 |
| 1673 | Polyunsaturated fatty acid levels | GCST90502618 | 10.46 |
| 1674 | CRLF1 levels | GCST90468868 | 10.45 |
| 1675 | BLMH levels | GCST90468447 | 10.45 |
| 1676 | UBA9475 sp002161235 abundance in stool | GCST90032635 | 10.45 |
| 1677 | ADH4/CA5A ratio | GCST90313189 | 10.45 |
| 1678 | Total lipids in large LDL | GCST90498011 | 10.45 |
| 1679 | Linoleic acid to total fatty acids percentage | GCST90502337 | 10.44 |
| 1680 | Neutrophil count | GCST90002352 | 10.43 |
| 1681 | Total protein levels | GCST90468105 | 10.43 |
| 1682 | Polycystic ovarian syndrome, broad definition | FING00001183 | 10.43 |
| 1683 | TGFBI levels | GCST90470845 | 10.40 |
| 1684 | DCBLD2 levels | GCST90468952 | 10.40 |
| 1685 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90499288 | 10.39 |
| 1686 | 3-Hydroxybutyrate levels | GCST90092811 | 10.38 |
| 1687 | FOXO1/NUB1 ratio | GCST90314874 | 10.38 |
| 1688 | Plasma pregnenetriol disulfate* levels in chronic kidney disease | GCST90265864 | 10.38 |
| 1689 | White blood cell count | GCST90002375 | 10.38 |
| 1690 | TMSB10/TREML2 ratio | GCST90315923 | 10.37 |
| 1691 | COLEC12/LTBR ratio | GCST90314182 | 10.37 |
| 1692 | Total cholesterol minus HDL-C levels | GCST90499129 | 10.37 |
| 1693 | DKK1/LGALS8 ratio | GCST90314472 | 10.36 |
| 1694 | ANXA3/ENO2 ratio | GCST90313281 | 10.36 |
| 1695 | Total lipids in small VLDL (UKB data field 23510) | GCST90269607 | 10.36 |
| 1696 | CALCOCO1/DCTN1 ratio | GCST90313600 | 10.36 |
| 1697 | MRPL33 levels | GCST90617986 | 10.36 |
| 1698 | SERPIND1 levels | GCST90470595 | 10.35 |
| 1699 | Phospholipids to total lipids ratio in medium HDL | GCST90092901 | 10.34 |
| 1700 | APBB1IP levels | GCST90468327 | 10.34 |
| 1701 | IL2RA levels | GCST90469585 | 10.33 |
| 1702 | ASAH2 levels | GCST90468374 | 10.33 |
| 1703 | Clinical LDL cholesterol levels | GCST90497219 | 10.32 |
| 1704 | Concentration of LDL particles | GCST90498413 | 10.31 |
| 1705 | CLEC1A/TNFRSF1A ratio | GCST90314085 | 10.31 |
| 1706 | PLG levels | GCST90470257 | 10.31 |
| 1707 | Posterior diffusion tensor imaging along the perivascular space index | GCST90455545 | 10.31 |
| 1708 | Triglycerides | GCST000758 | 10.30 |
| 1709 | CFH levels | GCST90468729 | 10.29 |
| 1710 | DUSP3 levels | GCST90469053 | 10.29 |
| 1711 | FABP3 levels | GCST90469175 | 10.29 |
| 1712 | Total lipid levels in small VLDL | GCST90092974 | 10.27 |
| 1713 | ADGRE5/SEMA7A ratio | GCST90313183 | 10.27 |
| 1714 | Left ventricular end systole anterolateral wall thickness | GCST90278511 | 10.26 |
| 1715 | Triglyceride levels in HDL | GCST90092829 | 10.26 |
| 1716 | Docosahexaenoic acid to total fatty acids percentage | GCST90501999 | 10.26 |
| 1717 | CD86 levels | GCST90468654 | 10.25 |
| 1718 | Whole grain cereal liking | GCST90094869 | 10.25 |
| 1719 | Cholesterol in Small LDL | GCST90499559 | 10.25 |
| 1720 | Triglycerides in medium LDL | GCST90498870 | 10.25 |
| 1721 | Type 2 diabetes | GCST90086072 | 10.25 |
| 1722 | Total cholesterol levels | GCST90239675 | 10.24 |
| 1723 | CCL11 levels | GCST90468564 | 10.24 |
| 1724 | CCL17 levels | GCST90468569 | 10.23 |
| 1725 | IDP dMRI TBSS OD Genu of corpus callosum | GCST90004404 | 10.23 |
| 1726 | Maximum heart rate during fitness test | ECG during exercise | UKBB00000431 | 10.22 |
| 1727 | CASP8/SEPTIN9 ratio | GCST90313658 | 10.22 |
| 1728 | BSG/CKAP4 ratio | GCST90313531 | 10.22 |
| 1729 | Phospholipids to Total Lipids in Large LDL percentage | GCST90498071 | 10.21 |
| 1730 | Alkylphosphatidylcholine (O-32:1) levels | GCST90024923 | 10.20 |
| 1731 | EPPK1 levels | GCST90469137 | 10.20 |
| 1732 | CASP3/PDGFB ratio | GCST90313638 | 10.19 |
| 1733 | MMP1/SERPINB6 ratio | GCST90315462 | 10.19 |
| 1734 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502147 | 10.18 |
| 1735 | Rubneribacter sp002159915 abundance in stool | GCST90032541 | 10.18 |
| 1736 | EBAG9/HBEGF ratio | GCST90314565 | 10.18 |
| 1737 | MFAP4 levels | GCST90469898 | 10.17 |
| 1738 | APBB1IP/NADK ratio | GCST90313298 | 10.17 |
| 1739 | Phospholipid levels in VLDL | GCST90093001 | 10.17 |
| 1740 | Tea without sugar liking | GCST90094858 | 10.17 |
| 1741 | DAB2/TBL1X ratio | GCST90314368 | 10.16 |
| 1742 | CA4/SELE ratio | GCST90313587 | 10.16 |
| 1743 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498101 | 10.15 |
| 1744 | IDP dMRI TBSS L2 Retrolenticular part of internal capsule R | GCST90004143 | 10.14 |
| 1745 | FUS levels | GCST90469278 | 10.14 |
| 1746 | Conjunctivitis | FING00000346 | 10.13 |
| 1747 | IDP SWI T2star left pallidum | GCST90003869 | 10.13 |
| 1748 | COMP/ICAM1 ratio | GCST90314189 | 10.12 |
| 1749 | Free Cholesterol to Total Lipids in Medium LDL percentage | GCST90498783 | 10.10 |
| 1750 | TNFSF10 levels | GCST90470917 | 10.10 |
| 1751 | Free cholesterol to total lipids ratio in very large VLDL | GCST90093021 | 10.10 |
| 1752 | CCN3/FAP ratio | GCST90313721 | 10.08 |
| 1753 | TMEM106A levels | GCST90470886 | 10.07 |
| 1754 | DCTN1/TRIAP1 ratio | GCST90314434 | 10.07 |
| 1755 | Triglycerides to total lipids in medium HDL percentage (UKB data field 23643) | GCST90269740 | 10.06 |
| 1756 | CLEC4G/MERTK ratio | GCST90314121 | 10.06 |
| 1757 | Positional arithmetic | Fluid intelligence / reasoning | UKBB00000654 | 10.05 |
| 1758 | CCN1 levels | GCST90468587 | 10.04 |
| 1759 | CCL20 levels | GCST90468572 | 10.04 |
| 1760 | CRADD/STAMBP ratio | GCST90314244 | 10.03 |
| 1761 | SEZ6L2 levels | GCST90470606 | 10.03 |
| 1762 | Phospholipids to Total Lipids in Small LDL percentage | GCST90499700 | 10.02 |
| 1763 | Left-hemisphere visual network to accumbens white-matter structural connectivity | GCST90302668 | 10.02 |
| 1764 | CSF1/SEMA3F ratio | GCST90314288 | 10.02 |
| 1765 | GART levels | GCST90469303 | 10.02 |
| 1766 | SETMAR levels | GCST90470605 | 10.01 |
| 1767 | BST2/CXADR ratio | GCST90313538 | 10.00 |
| 1768 | Triglycerides x anxiety interaction (2df test) | GCST90570677 | 9.98 |
| 1769 | PSAP levels | GCST90426586 | 9.98 |
| 1770 | IL17RB levels | GCST90469563 | 9.98 |
| 1771 | KLKB1 levels | GCST90469708 | 9.97 |
| 1772 | Phospholipids to total lipids in medium HDL percentage (UKB data field 23639) | GCST90269736 | 9.97 |
| 1773 | EIF4G1/NFATC1 ratio | GCST90314637 | 9.96 |
| 1774 | Omega-3 fatty acids to total fatty acids percentage | GCST90502088 | 9.96 |
| 1775 | KYNU/SCLY ratio | GCST90315265 | 9.93 |
| 1776 | GP1BA/SIAE ratio | GCST90314959 | 9.93 |
| 1777 | Cardiovascular disease | GCST90086057 | 9.93 |
| 1778 | CD22 levels | GCST90468610 | 9.93 |
| 1779 | Certain disorders involving the immune mechanism | FING00000264 | 9.92 |
| 1780 | MMP3 levels | GCST90469920 | 9.92 |
| 1781 | MOG/SEZ6L ratio | GCST90315477 | 9.92 |
| 1782 | Witnessed sudden violent death | Traumatic events | UKBB00000917 | 9.91 |
| 1783 | DBNL/PDGFB ratio | GCST90314422 | 9.90 |
| 1784 | TNFSF14 levels | GCST90470922 | 9.89 |
| 1785 | Free Cholesterol to Total Lipids in Large LDL percentage | GCST90498000 | 9.89 |
| 1786 | Medication for pain relief, constipation, heartburn - Laxatives (e.g. Dulcolax, Senokot) | Medication | UKBB00000456 | 9.88 |
| 1787 | Cholesteryl esters to total lipids ratio in large VLDL | GCST90092871 | 9.87 |
| 1788 | Other degenerative diseases of the nervous system | FING00000994 | 9.87 |
| 1789 | Triglycerides to Total Lipids in Large HDL percentage | GCST90497906 | 9.87 |
| 1790 | Cholesterol to total lipids ratio in medium VLDL | GCST90092917 | 9.85 |
| 1791 | FGFBP3 levels | GCST90469232 | 9.83 |
| 1792 | SIGLEC7 levels | GCST90470635 | 9.83 |
| 1793 | PAMR1 levels | GCST90470155 | 9.83 |
| 1794 | Sphingomyelin_42:2_[M+OAc]1- levels | GCST90060507 | 9.83 |
| 1795 | Physical activity (Total log acceleration) | GCST90061408 | 9.82 |
| 1796 | NECTIN2/TNFRSF1A ratio | GCST90315532 | 9.82 |
| 1797 | Polyunsaturated fatty acids levels (UKB data field 23446) | GCST90269543 | 9.82 |
| 1798 | Triglycerides to total lipids ratio in chylomicrons and extremely large VLDL | GCST90093051 | 9.82 |
| 1799 | Triacylglycerol_46:4_[M+NH4]1+ levels | GCST90060362 | 9.81 |
| 1800 | LCN2/RETN ratio | GCST90315308 | 9.81 |
| 1801 | CD22/FCRL1 ratio | GCST90313757 | 9.81 |
| 1802 | NPY/SMOC1 ratio | GCST90315551 | 9.80 |
| 1803 | ITGB1/REG1A ratio | GCST90315228 | 9.79 |
| 1804 | Volume of right medial nucleus | GCST90475045 | 9.79 |
| 1805 | GFAP levels | GCST90469325 | 9.78 |
| 1806 | Free Cholesterol to Total Lipids in Very Large HDL percentage | GCST90500397 | 9.78 |
| 1807 | IBD (strict) with PSC | FING00000657 | 9.77 |
| 1808 | SLC39A5 levels | GCST90470661 | 9.76 |
| 1809 | LILRB1 levels | GCST90469776 | 9.76 |
| 1810 | Pain type(s) experienced in last month - Pain all over the body | Pain | UKBB00000632 | 9.75 |
| 1811 | IDP dMRI ProbtrackX FA cgc r | GCST90003930 | 9.75 |
| 1812 | Skin luminance | GCST90320257 | 9.73 |
| 1813 | PI16 levels | GCST90470229 | 9.73 |
| 1814 | IDP T1 SIENAX white unnormalised volume | GCST90002433 | 9.72 |
| 1815 | Triglycerides in chylomicrons and extremely large VLDL (UKB data field 23487) | GCST90269584 | 9.70 |
| 1816 | SSC-A on plasmacytoid Dendritic Cell | GCST90002072 | 9.69 |
| 1817 | Abdominal subcutaneous adipose tissue | GCST90267347 | 9.69 |
| 1818 | COLEC12/NBL1 ratio | GCST90314183 | 9.68 |
| 1819 | Visceral adipose tissue | GCST90267357 | 9.68 |
| 1820 | IL32 levels | GCST90469591 | 9.67 |
| 1821 | CALCOCO1/CASP8 ratio | GCST90313597 | 9.66 |
| 1822 | Mineral and other dietary supplements - Calcium | Medication | UKBB00000471 | 9.66 |
| 1823 | SRPX levels | GCST90470744 | 9.65 |
| 1824 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502399 | 9.65 |
| 1825 | Triglycerides in HDL (UKB data field 23410) | GCST90269507 | 9.65 |
| 1826 | ERBIN/SNAP29 ratio | GCST90314697 | 9.64 |
| 1827 | CD14 levels | GCST90468598 | 9.63 |
| 1828 | SMAD5 levels | GCST90470678 | 9.63 |
| 1829 | aparc-DKTatlas rh area insula | GCST90003296 | 9.60 |
| 1830 | IDP dMRI ProbtrackX ICVF ifo l | GCST90004387 | 9.60 |
| 1831 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502648 | 9.60 |
| 1832 | Acute appendicitis, with complications | FING00000019 | 9.59 |
| 1833 | Triglycerides to Total Lipids in Large LDL percentage | GCST90498092 | 9.59 |
| 1834 | IDP dMRI TBSS FA Retrolenticular part of internal capsule R | GCST90003897 | 9.58 |
| 1835 | Left-hemisphere visual network to pallidum white-matter structural connectivity | GCST90302665 | 9.57 |
| 1836 | Concentration of large LDL particles | GCST90498037 | 9.57 |
| 1837 | PALM3 levels | GCST90470153 | 9.57 |
| 1838 | Free cholesterol in VLDL (UKB data field 23420) | GCST90269517 | 9.56 |
| 1839 | SOST/SPP1 ratio | GCST90315871 | 9.56 |
| 1840 | SPARC/TJAP1 ratio | GCST90315873 | 9.56 |
| 1841 | CTSZ/SMPDL3A ratio | GCST90314322 | 9.56 |
| 1842 | Triglycerides in very large HDL (UKB data field 23557) | GCST90269654 | 9.55 |
| 1843 | CDKN1A/FOXO1 ratio | GCST90313970 | 9.55 |
| 1844 | KLK8 levels | GCST90241680 | 9.55 |
| 1845 | Ratio of linoleic acid to total fatty acids | GCST90092881 | 9.55 |
| 1846 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502075 | 9.54 |
| 1847 | IDP dMRI ProbtrackX ICVF ilf r | GCST90004390 | 9.54 |
| 1848 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio (UKB data field 23458) | GCST90269555 | 9.53 |
| 1849 | FCER1A levels | GCST90469198 | 9.53 |
| 1850 | IDP dMRI TBSS ICVF Sagittal stratum R | GCST90004357 | 9.53 |
| 1851 | SIAE levels | GCST90470629 | 9.53 |
| 1852 | KIT levels | GCST90469692 | 9.53 |
| 1853 | Triacylglycerol (54:2) [NL-18:0] levels | GCST90025175 | 9.52 |
| 1854 | Cholesterol, total | GCST000760 | 9.52 |
| 1855 | Free cholesterol levels in very large HDL | GCST90132680 | 9.50 |
| 1856 | Irritable bowel syndrome | GCST90243958 | 9.50 |
| 1857 | CXCL13 levels | GCST90468926 | 9.50 |
| 1858 | ASGR1 levels | GCST90468375 | 9.49 |
| 1859 | CD69/F2R ratio | GCST90313877 | 9.49 |
| 1860 | CD226 levels | GCST90468609 | 9.49 |
| 1861 | Alkylphosphatidylcholine (O-34:1) levels | GCST90025551 | 9.48 |
| 1862 | Triglycerides to Total Lipids in Very Large HDL percentage | GCST90500508 | 9.48 |
| 1863 | LCN2/PRTN3 ratio | GCST90315307 | 9.47 |
| 1864 | Non-HDL cholesterol levels | GCST90239669 | 9.45 |
| 1865 | GBA1 levels | GCST90423262 | 9.44 |
| 1866 | CA4/TNFSF12 ratio | GCST90313589 | 9.44 |
| 1867 | SNCA levels | GCST90240258 | 9.44 |
| 1868 | TMEM25 levels | GCST90470888 | 9.43 |
| 1869 | Illnesses of mother: Alzheimer's disease/dementia (UKB data field 20110_10) | GCST90042678 | 9.43 |
| 1870 | Free cholesterol to total lipids ratio in very small VLDL | GCST90093033 | 9.42 |
| 1871 | SHBG levels | GCST90503315 | 9.42 |
| 1872 | CCL3 levels | GCST90468582 | 9.41 |
| 1873 | Triglycerides to Total Lipids in IDL percentage | GCST90497676 | 9.41 |
| 1874 | CRADD/EREG ratio | GCST90314236 | 9.41 |
| 1875 | GFRA3 levels | GCST90469330 | 9.40 |
| 1876 | Benign neoplasm: Choroid | FING00000170 | 9.40 |
| 1877 | CXCL11/SDC4 ratio | GCST90314336 | 9.39 |
| 1878 | USP8/WASF1 ratio | GCST90315944 | 9.39 |
| 1879 | PDGFB/SDC4 ratio | GCST90315626 | 9.38 |
| 1880 | Carnitine levels | GCST90239991 | 9.38 |
| 1881 | CLEC1B/ITGB5 ratio | GCST90314094 | 9.38 |
| 1882 | LEPR/NRCAM ratio | GCST90315312 | 9.37 |
| 1883 | C1S levels | GCST90468494 | 9.36 |
| 1884 | Triglycerides in very small VLDL (UKB data field 23522) | GCST90269619 | 9.36 |
| 1885 | NID1/SORT1 ratio | GCST90315542 | 9.35 |
| 1886 | SORT1 levels | GCST90470710 | 9.35 |
| 1887 | FCRL5/TNFRSF13B ratio | GCST90314805 | 9.34 |
| 1888 | CRTAC1 levels | GCST90468870 | 9.34 |
| 1889 | GFRA1 levels | GCST90469328 | 9.34 |
| 1890 | Total Phosphatidylethanolamine levels | GCST90025207 | 9.33 |
| 1891 | Lung adenocarcinoma | GCST004744 | 9.32 |
| 1892 | Diseases of middle ear and mastoid | FING00000427 | 9.31 |
| 1893 | Facial pigmentation measurement (UV light) | GCST90002283 | 9.31 |
| 1894 | CANT1/HSPB1 ratio | GCST90313617 | 9.30 |
| 1895 | HBEGF/PLXNA4 ratio | GCST90315036 | 9.29 |
| 1896 | KIFBP/TBC1D23 ratio | GCST90315250 | 9.29 |
| 1897 | Omega-3 fatty acids to total fatty acids percentage | GCST90499163 | 9.29 |
| 1898 | CPA4 levels | GCST90468838 | 9.29 |
| 1899 | KIR2DL2 levels | GCST90469684 | 9.28 |
| 1900 | Left-hemisphere limbic network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302732 | 9.28 |
| 1901 | Cholesteryl Esters to Total Lipids in Very Large VLDL percentage | GCST90500569 | 9.27 |
| 1902 | LY6D/PLA2G10 ratio | GCST90315345 | 9.26 |
| 1903 | LPO levels | GCST90469789 | 9.26 |
| 1904 | F-fruit liking (derived food-liking factor) | GCST90094767 | 9.26 |
| 1905 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 9.26 |
| 1906 | X-03056--N-[3- 2-Oxopyrrolidin-1-yl propyl]acetamide levels | GCST90243619 | 9.26 |
| 1907 | Free Cholesterol in LDL | GCST90498386 | 9.25 |
| 1908 | MAX/TDRKH ratio | GCST90315406 | 9.25 |
| 1909 | FADD/NFATC1 ratio | GCST90314771 | 9.25 |
| 1910 | Triglycerides to Total Lipids in Medium HDL percentage | GCST90498682 | 9.25 |
| 1911 | Saturated fatty acids levels | GCST90502186 | 9.24 |
| 1912 | Total lipid levels in lipoprotein particles | GCST90092989 | 9.23 |
| 1913 | ATOX1/SPARC ratio | GCST90313375 | 9.23 |
| 1914 | CRHBP levels | GCST90468860 | 9.23 |
| 1915 | EGLN1/FOXO1 ratio | GCST90314616 | 9.22 |
| 1916 | IDI2 levels | GCST90469505 | 9.22 |
| 1917 | VWC2 levels | GCST90471064 | 9.21 |
| 1918 | IDP dMRI ProbtrackX ICVF ilf l | GCST90004389 | 9.21 |
| 1919 | CA5A/GSTA1 ratio | GCST90313591 | 9.20 |
| 1920 | Cholesterol | Blood biochemistry | UKBB00000134 | 9.19 |
| 1921 | CXCL11/CXCL13 ratio | GCST90314333 | 9.19 |
| 1922 | RECK levels | GCST90470445 | 9.19 |
| 1923 | IL1RN levels | GCST90012004 | 9.18 |
| 1924 | IDP T1 SIENAX white normalised volume | GCST90002432 | 9.18 |
| 1925 | FCGR2B levels | GCST90469201 | 9.17 |
| 1926 | Crohn disease (strict definition, require KELA, min 2 HDR) | FING00000366 | 9.17 |
| 1927 | Free cholesterol in large HDL | GCST90497780 | 9.16 |
| 1928 | KLK11 levels | GCST90469697 | 9.15 |
| 1929 | Triglyceride levels in LDL | GCST90092890 | 9.13 |
| 1930 | Average diameter for HDL particles | GCST90132702 | 9.13 |
| 1931 | IDP dMRI ProbtrackX L1 cgc r | GCST90004251 | 9.13 |
| 1932 | EDAR/TNFSF12 ratio | GCST90314591 | 9.13 |
| 1933 | DNMBP/TJAP1 ratio | GCST90314521 | 9.12 |
| 1934 | DIABLO/MITD1 ratio | GCST90314467 | 9.11 |
| 1935 | Docosahexaenoic acid levels | GCST90497252 | 9.11 |
| 1936 | DTI autoptx L2 cgc r tract | GCST90385171 | 9.10 |
| 1937 | CD83/IL12A_IL12B ratio | GCST90313905 | 9.10 |
| 1938 | C19ORF12 levels | GCST90468483 | 9.10 |
| 1939 | Sardines liking | GCST90094830 | 9.09 |
| 1940 | Otosclerosis | GCST90129575 | 9.09 |
| 1941 | IL6ST/LEPR ratio | GCST90315165 | 9.08 |
| 1942 | Alzheimer's disease (MTAG) | GCST90449062 | 9.08 |
| 1943 | HSPG2/SMOC2 ratio | GCST90315093 | 9.06 |
| 1944 | CD84/CDKN1A ratio | GCST90313909 | 9.06 |
| 1945 | Total fatty acid levels | GCST90502212 | 9.05 |
| 1946 | GLB1 levels | GCST90469355 | 9.04 |
| 1947 | SERPINA9 levels | GCST90470588 | 9.04 |
| 1948 | Triglycerides to Total Lipids in Medium HDL percentage | GCST90498689 | 9.03 |
| 1949 | Citrate levels | GCST90497206 | 9.03 |
| 1950 | Sphingomyelin_40:0_[M+H]1+ levels | GCST90060364 | 9.03 |
| 1951 | Coffee difference liking | GCST90094738 | 9.03 |
| 1952 | Polyunsaturated fatty acid levels | GCST90502140 | 9.02 |
| 1953 | Acetoacetate levels | GCST90092804 | 9.01 |
| 1954 | Total protein levels | UKBB00000826 | 9.01 |
| 1955 | Triglycerides to Total Lipids in IDL percentage | GCST90497682 | 9.01 |
| 1956 | MDH1 levels | GCST90469876 | 9.01 |
| 1957 | Omega-6 fatty acid levels | GCST90502095 | 9.00 |
| 1958 | CDH17 levels | GCST90468669 | 9.00 |
| 1959 | Polymyalgia rheumatica | FING00001188 | 9.00 |
| 1960 | Other strabismus | FING00001114 | 8.99 |
| 1961 | DCTN1/FXN ratio | GCST90314430 | 8.98 |
| 1962 | Triglycerides in IDL | GCST90497671 | 8.98 |
| 1963 | lymphocyte (fraction, maximum, inv-norm transformed) | GCST90475432 | 8.98 |
| 1964 | FCAR levels | GCST90469197 | 8.96 |
| 1965 | Job SOC coding: Heavy goods vehicle drivers (UKB data field 22617_8211) | GCST90043552 | 8.96 |
| 1966 | aseg rh intensity Caudate | GCST90003783 | 8.95 |
| 1967 | Crohn's disease of large intestine | FING00000368 | 8.94 |
| 1968 | CCL15/CCL23 ratio | GCST90313681 | 8.92 |
| 1969 | IDP SWI T2star right caudate | GCST90003866 | 8.92 |
| 1970 | ASGR1/DCBLD2 ratio | GCST90313364 | 8.89 |
| 1971 | CRADD/HSPA1A ratio | GCST90314239 | 8.88 |
| 1972 | Barrett's esophagus | GCST003738 | 8.88 |
| 1973 | IDP T1 FAST ROIs R cerebellum V | GCST90002565 | 8.87 |
| 1974 | NCAN levels | GCST90470005 | 8.87 |
| 1975 | COL1A1 levels | GCST90468813 | 8.87 |
| 1976 | F-burn/spicy liking (derived food-liking factor) | GCST90094716 | 8.87 |
| 1977 | CD22/FCER2 ratio | GCST90313756 | 8.86 |
| 1978 | CEP43 levels | GCST90468715 | 8.84 |
| 1979 | Docosahexaenoic acid levels | GCST90501986 | 8.84 |
| 1980 | Mean bone marrow fat fraction of thoracic vertebrae 8-12 | GCST90652385 | 8.83 |
| 1981 | IDP dMRI ProbtrackX ICVF ifo r | GCST90004388 | 8.83 |
| 1982 | Free cholesterol to total lipids in large HDL percentage (UKB data field 23637) | GCST90269734 | 8.82 |
| 1983 | LGALS3 levels | GCST90469761 | 8.82 |
| 1984 | Omega-3 fatty acid levels | GCST90502425 | 8.81 |
| 1985 | Right-hemisphere limbic network to hippocampus white-matter structural connectivity | GCST90302831 | 8.81 |
| 1986 | BAG6/USP8 ratio | GCST90313451 | 8.81 |
| 1987 | MYL3 levels | GCST90469977 | 8.79 |
| 1988 | Myocardial fractal dimension (slice 6) | GCST90000292 | 8.79 |
| 1989 | 1-stearoyl-2-linoleoyl-GPI (18:0/18:2) levels | GCST90200067 | 8.78 |
| 1990 | LY6G6C levels | GCST90241830 | 8.78 |
| 1991 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T230 | ECGU000230 | 8.77 |
| 1992 | Docosahexaenoic acid levels | GCST90502242 | 8.75 |
| 1993 | NOS3 levels | GCST90470064 | 8.75 |
| 1994 | HSPG2/VASN ratio | GCST90315094 | 8.74 |
| 1995 | B4GALT1/SPON2 ratio | GCST90313434 | 8.74 |
| 1996 | APP/TMSB10 ratio | GCST90313332 | 8.74 |
| 1997 | White blood cell count | GCST90018758 | 8.73 |
| 1998 | DCTN6 levels | GCST90468960 | 8.73 |
| 1999 | CD244 levels | GCST90274771 | 8.72 |
| 2000 | Phospholipids to total lipids in very large HDL percentage (UKB data field 23629) | GCST90269726 | 8.72 |